Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

Treatment Clinical Trials for Advanced Carcinoma Of Unknown Primary

Review the advanced carcinoma of unknown primary treatment clinical trials on this list and use the filters to refine the results by age and location. Some clinical trials are held at NCI-Designated Cancer Centers and may be supported by other organizations.

You can find more information about the types and phases of clinical trials and what to expect or use our Steps to Find a Clinical Trial.

Trials 1-25 of 25

Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer after Previous Treatment
Status: Active
Location: 152 locations
Testing the Addition of Ipatasertib to Usual Chemotherapy and Radiation for Head and Neck Cancer
Status: Active
Location: 17 locations
Alternating Chemoimmunotherapy and Immunotherapy Treatment Plans for the Treatment of Stage IV Lung Cancer or Head and Neck Cancers, The ATATcH Study
Status: Active
Location: 11 locations
A Study Comparing Personalized Radiation Therapy with Standard Radiation Therapy in People With HPV-Positive Throat Cancer
Status: Active
Location: 9 locations
Intensity Modulated Proton Therapy or Intensity Modulated X-Ray Therapy after Surgery for the Treatment of Head and Neck Cancer, the HEADLIGHT Study
Status: Active
Location: 8 locations
Low-Dose Radiation Therapy with Standard Chemotherapy for the Treatment of Patients with Human Papillomavirus-Associated Stage I-IVa Oropharyngeal Cancer
Status: Active
Location: 7 locations
Radiation Therapy and Chemotherapy De-escalation Prior to Neck Dissection Surgery for the Treatment of Laryngeal, Hypopharyngeal, or p16-Negative Oropharyngeal and Unknown Primary Head and Neck Squamous Cell Cancers
Status: Active
Location: 7 locations
Evaluating Residual Circulating Tumor DNA Levels After Surgery for Directing Adjuvant Treatment in Patients with HPV-Mediated Oropharynx Cancer, SAVAL Trial
Status: Active
Location: 5 locations
DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers
Status: Active
Location: 5 locations
Accelerated Fractionation Radiotherapy versus Conventional Fractionation Radiotherapy for the Treatment of Head and Neck Squamous Cell Cancer Greater than 6 Weeks after Surgery, PORTRush Trial
Status: Active
Location: 3 locations
Pembrolizumab and Cabozantinib in Treating Patients with Recurrent or Metastatic Head and Neck Squamous Cell Cancer That Cannot Be Removed by Surgery
Status: Active
Location: 3 locations
Neratinib and Trastuzumab Deruxtecan for the Treatment of HER2 Overexpressing Unresectable or Metastatic Gastrointestinal Cancer
Status: Active
Location: 3 locations
Lovastatin and Pembrolizumab for the Treatment of Patients with Recurrent or Metastatic Head and Neck Cancer, LAPP Trial
Status: Active
Location: 2 locations
Atezolizumab and Tiragolumab for the Treatment of Patients with Refractory Locally Advanced, Metastatic or Recurrent Cancer of Unknown Primary
Status: Active
Location: M D Anderson Cancer Center, Houston, Texas
Cetuximab and Cemiplimab before Surgery for the Treatment of Resectable Head and Neck Squamous Cell Cancer
Status: Active
Location: Moffitt Cancer Center, Tampa, Florida
Risk-Directed Postoperative Radiation Therapy and Cisplatin for the Treatment of Stage I-II HPV-Related Oropharynx Squamous Cell Carcinoma, The Minimalist Trial-2 (MINT-2)
Status: Active
Location: Siteman Cancer Center at Washington University, Saint Louis, Missouri
Personalized Treatment with Surgery, Radiation and/or Chemotherapy for Patients with Stage I-II HPV-related Squamous Cell Carcinoma of the Oropharynx
Status: Active
Location: University of Michigan Comprehensive Cancer Center, Ann Arbor, Michigan
Radiotherapy Dose De-escalation for the Treatment of HPV-Associated Cancers of the Oropharynx
Status: Active
Location: Duke University Medical Center, Durham, North Carolina
Nivolumab in Combination with BMS-986253 or Cabiralizumab Before Surgery for the Treatment of Newly Diagnosed Surgically Resectable, Recurrent or Metastatic Head and Neck Cancer, SPARK2 Study
Status: Active
Location: Johns Hopkins University/Sidney Kimmel Cancer Center, Baltimore, Maryland
Pembrolizumab and QUAD SHOT Radiation Therapy for the Treatment of Locally Advanced, Metastatic, or Recurrent Head and Neck Squamous Cell Cancer
Status: Active
Location: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
Pembrolizumab and Radiation Therapy Before and During Surgery for the Treatment of Persistent or Recurrent Head and Neck Cancer
Status: Active
Location: Ohio State University Comprehensive Cancer Center, Columbus, Ohio
gFOLFOXIRITAX Regimen for the Treatment of Locally Advanced or Metastatic Upper Gastrointestinal Adenocarcinoma, I-FLOAT Study
Status: Active
Location: University of Chicago Comprehensive Cancer Center, Chicago, Illinois
TMV Vaccine Therapy alone and with Pembrolizumab for the Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Cancer
Status: Active
Location: 2 locations
Olanzapine for Managing Anorexia in Head and Neck Cancer Patients Undergoing Chemoradiation, MACRO Trial
Status: Approved
Location: Roswell Park Cancer Institute, Buffalo, New York
Pembrolizumab in Treating Patients with Rare Tumors That Cannot Be Removed by Surgery or are Metastatic
Status: Temporarily Closed to Accrual
Location: M D Anderson Cancer Center, Houston, Texas